Abbott
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Abbott sits in the top decile of US sponsors by registered trial count (#166 of 15,742 sponsors by registered trial count).
Abbott: 181 sponsored US clinical trials, none currently recruiting.
Abbott sponsors 181 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 158 completed. 90 of these trials are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 7 trials.
Top-decile sponsor footprint
Abbott ranks in the top decile of sponsors by registered trial count (#166 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
158 of 181 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
181 total, page 1 of 4
A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.
NCT01464320
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
NCT01482845
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
NCT01506934
A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
NCT01286974
Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
NCT01401933
A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia
NCT01545310
To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.
NCT01381341
Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.
NCT01346319
Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
NCT01181427
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness
NCT01124851
To Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors
NCT01193140
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
NCT01114191
Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450
NCT01091649
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).
NCT01021358
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
NCT01009593
A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults
NCT01050127
Exploratory Biomarker Study of Cerebrospinal Fluid in Healthy Volunteers
NCT01126567
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
NCT00977080
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
NCT01043458
A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid
NCT01009216
Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects
NCT01053520
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
NCT00982826
A Study to Investigate the Process by Which ABT-614 is Absorbed, Distributed, Metabolized and Eliminated in Humans
NCT00959816
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects
NCT00968422
Pharmacokinetic Study of ABT-126 in Healthy Volunteers
NCT00959634
Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation
NCT00947440
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
NCT00888108
Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers
NCT00912431
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
NCT00931281
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet
NCT00909636
Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
NCT00909311
Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
NCT00918255
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C
NCT00890318
Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers
NCT00895102
A Safety and Tolerability Study of ABT-126 in Elderly
NCT00867399
A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects
NCT00854659
Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules
NCT00839293
Phase 1 BA Study, Single Center With Healthy Volunteers
NCT00870948
The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5
NCT00616902
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
NCT00809510
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333
NCT00768690
A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults
NCT00752687
Assess the Oral Bioavailability of New ABT-263 Formulations
NCT00743028
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
NCT00735787
A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
NCT00743470
A Trial of PDL192 in Subjects With Advanced Solid Tumors
NCT00738764
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
NCT00711009
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty
NCT00635817
A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
NCT00726869
A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe
NCT00681525
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 37 |
| Phase 3 | 71 |
| Phase 4 | 19 |
How the Abbott archive is shaped
181 indexed studies, none listed as recruiting (0% open); 158 completed (87%).
Phase mix: 90 late (III/IV) vs 83 early (I/II) (balanced across stages).
Top condition: Healthy (7 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Abbott: archived-pipeline peers nationwide
Peers matched on 181 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Abbott sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 181 archived trials
- ViiV Healthcare · 182 trials · 4% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
- Fox Chase Cancer Center · 183 trials · 16% recruiting
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Abbott page
181 registered trials is a research-attention snapshot, not an endorsement of Abbott or any single study.
- None of Abbott's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition Abbott studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abbott pipeline card: 181 registered trials from official public datasets.Report a data error.